SPHERA FUNDS MANAGEMENT LTD.
Position in APLS — Apellis Pharmaceuticals, Inc.
CIK 1496201
TEL AVIV, L3
Position in APLS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
+$0 QoQ
Shares Held
214,914
-14.4% QoQ
Ownership
0.168%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in APLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SPHERA FUNDS MANAGEMENT LTD. holds $446,413,848 across 71 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MLYS |
Mineralys Therapeutics, Inc.
|
1,469,971 | $39,659,817 | |
| 2 | SNDX |
Syndax Pharmaceuticals Inc
|
1,014,606 | $22,179,287 | |
| 3 | RARE |
Ultragenyx Pharmaceutical Inc.
|
588,494 | $19,649,814 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
328,550 | $18,799,631 | |
| 5 | CYTK |
Cytokinetics Inc
|
219,987 | $18,740,692 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
245,346 | $18,273,370 | |
| 7 | COGT |
Cogent Biosciences, Inc.
|
459,340 | $17,776,458 | |
| 8 | INSM |
INSMED Inc
|
118,800 | $12,666,456 |
All Filings in APLS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | 214,914 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | — | 250,961 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | — | 63,660 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | — | 114,346 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | — | 181,346 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | — | 206,251 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | — | 215,873 | Shares | Defined | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||